utilizing ar-targeted therapies in crpc
Published 6 years ago • 97 plays • Length 8:53Download video MP4
Download video MP3
Similar videos
-
8:30
ar-targeted therapies in crpc
-
8:33
the value of ar-targeted therapy in crpc
-
7:12
ep. 8: selecting optimal ar-targeted therapy for nmcrpc
-
9:00
differences between ar-targeted therapy in prostate cancer
-
2:34
ar-v7 as a biomarker in crpc
-
4:17
crpc: patient selection in ar-directed therapies
-
4:27
radium-223 as bone-targeted therapy for crpc
-
7:07
ep. 13: avoiding repeat lines of ar-targeted therapy in mcrpc
-
21:22
case study 3: crpc resistant to ar-directed therapies
-
0:57
dr. dorff on choosing between therapies in nonmetastatic crpc
-
6:08
treatment goals in m0 crpc
-
4:50
card trial: cabazitaxel after ar-targeted therapy in mcspc
-
3:06
how ar therapy has changed the nmcrpc treatment landscape
-
6:23
assessing treatment response in m0 crpc
-
6:13
ep. 7: current treatment and imaging options for nmcrpc
-
2:10
charles ryan, md: the differences in side effects between the two ar-targeted therapies
-
1:56
dr. oh on targeted treatment in metastatic castration-resistant prostate cancer
-
1:41
dr. antonarakis on ar-v7 and resistance to ar-targeting agents in mcrpc